Present and future drug treatments for chronic kidney diseases: evolving targets in renoprotection

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Nature reviews. Drug discovery

• Publication date

  2008-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/nrd2685PMID 18846102
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Paricalcitol inhibits renal inflammation by promoting vitamin D receptor-mediated sequestration of NF-kappaB signaling.

  2008cited by this paper
• Paricalcitol Reduces Albuminuria and Inflammation in Chronic Kidney Disease: A Randomized Double-Blind Pilot Trial

  2008cited by this paper
• The aggravating mechanisms of aldosterone on kidney fibrosis.

  2008cited by this paper
• Telmisartan, ramipril, or both in patients at high risk for vascular events.

  2008cited by this paper
• Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials

  2008cited by this paper
• Human Bone Marrow Mesenchymal Stem Cells Accelerate Recovery of Acute Renal Injury and Prolong Survival in Mice

  2008cited by this paper
• The Notch pathway in podocytes plays a role in the development of glomerular disease

  2008cited by this paper
• CDK/GSK-3 inhibitors as therapeutic agents for parenchymal renal diseases.

  2008cited by this paper
• Oral administration of GW788388, an inhibitor of TGF-beta type I and II receptor kinases, decreases renal fibrosis.

  2008cited by this paper
• Overview of factors contributing to the pathophysiology of progressive renal disease.

  2008cited by this paper
• A new look at platelet-derived growth factor in renal disease.

  2008cited by this paper
• Indirubin-3'-monoxime, a derivative of a Chinese anti-leukemia medicine, inhibits Notch1 signaling.

  2008cited by this paper
• Aliskiren combined with losartan in type 2 diabetes and nephropathy.

  2008cited by this paper
• Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review.

  2008cited by this paper
• Mechanisms of Disease: the role of aldosterone in kidney damage and clinical benefits of its blockade

  2007cited by this paper
• Hepatitis C virus: from entry to renal injury--facts and potentials.

  2007cited by this paper
• Rosiglitazone decreases albuminuria in type 2 diabetic patients.

  2007cited by this paper
• Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis.

  2007cited by this paper
• Cyclin-dependent kinase inhibition limits glomerulonephritis and extends lifespan of mice with systemic lupus.

  2007cited by this paper
• TNF-α neutralization ameliorates obstruction-induced renal fibrosis and dysfunction

  2007cited by this paper
• Rosiglitazone - : Continued uncertainty about safety

  2007cited by this paper
• Renoprotection Provided by Losartan in Combination with Pioglitazone Is Superior to Renoprotection Provided by Losartan Alone in Patients with Type 2 Diabetic Nephropathy

  2007cited by this paper
• Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-kappaB activation.

  2007cited by this paper
• The safety of rosuvastatin: effects on renal and hepatic function

  2007cited by this paper
• TNF-alpha neutralization ameliorates obstruction-induced renal fibrosis and dysfunction.

  2007cited by this paper
• Combination therapy with an angiotensin-converting enzyme inhibitor and a vitamin D analog suppresses the progression of renal insufficiency in uremic rats.

  2007cited by this paper
• Inhibition of gamma-secretases alters both proliferation and differentiation of mesenchymal stem cells.

  2007cited by this paper
• Latest treatment strategies for membranous nephropathy

  2007cited by this paper
• Inhibition of γ‐secretases alters both proliferation and differentiation of mesenchymal stem cells

  2007cited by this paper
• 1,25-Dihydroxyvitamin D3 targeting of NF-kappaB suppresses high glucose-induced MCP-1 expression in mesangial cells.

  2007cited by this paper
• Gene expression profiles of human proximal tubular epithelial cells in proteinuric nephropathies.

  2007cited by this paper
• Involvement of renal tubular Toll-like receptor 9 in the development of tubulointerstitial injury in systemic lupus.

  2007cited by this paper
• Fabry disease: Guidelines for the evaluation and management of multi-organ system involvement

  2006cited by this paper
• Podocyte Injury Underlies the Glomerulopathy of Dahl Salt-Hypertensive Rats and Is Reversed by Aldosterone Blocker

  2006cited by this paper
• Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes.

  2006cited by this paper
• Mechanisms of Disease: autosomal dominant and recessive polycystic kidney diseases

  2006cited by this paper
• Spironolactone ameliorates renal injury and connective tissue growth factor expression in type II diabetic rats.

  2006cited by this paper
• Connective tissue growth factor plays an important role in advanced glycation end product-induced tubular epithelial-to-mesenchymal transition: implications for diabetic renal disease.

  2006cited by this paper
• Therapeutic approaches in autosomal dominant polycystic kidney disease (ADPKD): is there light at the end of the tunnel?

  2006cited by this paper
• The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease.

  2006cited by this paper
• Permselective dysfunction of podocyte-podocyte contact upon angiotensin II unravels the molecular target for renoprotective intervention.

  2006cited by this paper
• Imatinib ameliorates renal disease and survival in murine lupus autoimmune disease.

  2006cited by this paper
• TNF-alpha bioactivity-inhibiting therapy in ANCA-associated vasculitis: clinical and experimental considerations.

  2006cited by this paper
• Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.

  2006cited by this paper
• The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria.

  2006cited by this paper
• Long-lasting arrest of murine polycystic kidney disease with CDK inhibitor roscovitine

  2006cited by this paper
• Discovery of 4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}-N-(tetrahydro-2H- pyran-4-yl)benzamide (GW788388): a potent, selective, and orally active transforming growth factor-beta type I receptor inhibitor.

  2006cited by this paper
• Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy.

  2006cited by this paper
• Podocyte injury and targeting therapy: an update

  2006cited by this paper
• Meta-Analysis: The Effect of Statins on Albuminuria

  2006cited by this paper
• Rituximab for idiopathic membranous nephropathy: who can benefit?

  2006cited by this paper
• Altered bone and mineral metabolism in patients receiving imatinib mesylate.

  2006cited by this paper
• The logic of TGFβ signaling

  2006cited by this paper
• Cardiotoxicity of the cancer therapeutic agent imatinib mesylate

  2006cited by this paper
• Wnt/beta-catenin signaling modulates survival of high glucose-stressed mesangial cells.

  2006cited by this paper
• Oral renin inhibitors.

  2006cited by this paper
• ACE inhibition reduces glomerulosclerosis and regenerates glomerular tissue in a model of progressive renal disease.

  2006cited by this paper
• CDK/GSK-3 inhibitors as a new approach for the treatment of proliferative renal diseases.

  2006cited by this paper
• Statins for improving renal outcomes: a meta-analysis.

  2006cited by this paper
• New capillary growth: a contributor to regression of sclerosis?

  2005cited by this paper
• Experimental membranous nephropathy redux.

  2005cited by this paper
• Limitation of podocyte proliferation improves renal function in experimental crescentic glomerulonephritis.

  2005cited by this paper
• Regression of existing glomerulosclerosis by inhibition of aldosterone.

  2005cited by this paper
• Inhibition of Gene Markers of Fibrosis with a Novel Inhibitor of Transforming Growth Factor-β Type I Receptor Kinase in Puromycin-Induced Nephritis

  2005cited by this paper
• Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease.

  2005cited by this paper
• Notch/γ-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells

  2005cited by this paper
• Macrophages and progressive tubulointerstitial disease.

  2005cited by this paper
• Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study.

  2005cited by this paper
• Antibody blockade of TNF-alpha reduces inflammation and scarring in experimental crescentic glomerulonephritis.

  2005cited by this paper
• Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice.

  2005cited by this paper
• Stimulation of Endothelial Progenitor Cells: A New Putative Therapeutic Effect of Angiotensin II Receptor Antagonists

  2005cited by this paper
• Therapeutics in Renal Disease: The Road Ahead for Antiproliferative Targets

  2005cited by this paper
• Aliskiren, a Human Renin Inhibitor, Ameliorates Cardiac and Renal Damage in Double-Transgenic Rats

  2005cited by this paper
• Antiproteinuric effect of oral paricalcitol in chronic kidney disease.

  2005cited by this paper
• Simvastatin attenuates renal inflammation, tubular transdifferentiation and interstitial fibrosis in rats with unilateral ureteral obstruction.

  2005cited by this paper
• CD20-positive infiltrates in human membranous glomerulonephritis.

  2005cited by this paper
• Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial.

  2005cited by this paper
• Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial.

  2005cited by this paper
• R-roscovitine (CYC202) alleviates renal cell proliferation in nephritis without aggravating podocyte injury.

  2005cited by this paper
• Beneficial impact of spironolactone in diabetic nephropathy.

  2005cited by this paper
• Local Renal Aldosterone System and Its Regulation by Salt, Diabetes, and Angiotensin II Type 1 Receptor

  2005cited by this paper
• Concepts in radiotherapy and immunotherapy: anti-CD20 mechanisms of action and targets.

  2005cited by this paper
• Vitamin D and its analogues: do they protect against cardiovascular disease in patients with kidney disease?

  2005cited by this paper
• Preventing microalbuminuria in type 2 diabetes.

  2004cited by this paper
• Endothelin-A Receptor Antagonism Reduces Blood Pressure and Increases Renal Blood Flow in Hypertensive Patients With Chronic Renal Failure: A Comparison of Selective and Combined Endothelin Receptor Blockade

  2004cited by this paper
• Human podocytes possess a stretch-sensitive, Ca2+-activated K+ channel: potential implications for the control of glomerular filtration.

  2004cited by this paper
• Cellular responses to protein overload: key event in renal disease progression

  2004cited by this paper
• The renal papilla is a niche for adult kidney stem cells.

  2004cited by this paper
• Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases

  2004cited by this paper
• Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease.

  2004cited by this paper
• Targeted Anticytokine Therapy in Patients With Chronic Heart Failure: Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL)

  2004cited by this paper
• The mouse kinome: discovery and comparative genomics of all mouse protein kinases.

  2004cited by this paper
• Reversal of collapsing glomerulopathy in mice with the cyclin-dependent kinase inhibitor CYC202.

  2004cited by this paper
• The effect of high glucose and PPAR-gamma agonists on PPAR-gamma expression and function in HK-2 cells.

  2004cited by this paper
• Connective tissue growth factor and renal diseases: some answers, more questions

  2004cited by this paper
• Pravastatin treatment attenuates interstitial inflammation and fibrosis in a rat model of chronic cyclosporine-induced nephropathy.

  2004cited by this paper
• Biopsy-verified response of severe lupus nephritis to treatment with rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to cyclophosphamide alone

  2004cited by this paper
• Activation of a local tissue angiotensin system in podocytes by mechanical strain.

  2004cited by this paper
• Mesenchymal stem cells are renotropic, helping to repair the kidney and improve function in acute renal failure.

  2004cited by this paper
• Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis.

  2004cited by this paper

• Estrategias de nefroprotección en pacientes con Enfermedad Renal Crónica: Una revisión narrativa de terapias farmacológicas y no farmacológicas

  2025cites this paper
• Efficacy and molecular mechanisms of natural polysaccharides in the treatment of kidney diseases

  2025cites this paper
• The potential adding therapeutic effect of pentoxifylline and/or folic acid for chronic kidney disease patients: randomized controlled trial

  2025cites this paper
• Impact of Nutritional Interventions on Alzheimer's Disease Progression: A Comprehensive Review of Dietary Patterns, Mechanisms, and Clinical Outcomes

  2024cites this paper
• Nephrotic Syndrome and Renin Angiotensin System: pathophysiological role and therapeutic potential.

  2022cites this paper
• Nanoformulations of flavonoids for diabetes and microvascular diabetic complications

  2022cites this paper
• A novel peptide ligand-coated nano-siRNA-lipoplex technology for kidney targeted gene therapy.

  2022cites this paper
• Bindarit Encapsulated Nanoparticles Prevent Venous Neointimal Hyperplasia and Restenosis in a Murine Angioplasty Model.

  2022cites this paper
• Renal Cell-Targeted Drug Delivery Strategy Based on Acute Kidney Injury and Chronic Kidney Disease: A Mini-Review.

  2021cites this paper
• Unravelling the Role of PAX2 Mutation in Human Focal Segmental Glomerulosclerosis

  2021influential citation
• PKNOX2 regulates myofibroblast functions and tubular cell survival during kidney fibrosis.

  2021cites this paper
• Kidney-targeted therapies: A quantitative perspective.

  2020cites this paper
• Morin hydrate attenuates adenine-induced renal fibrosis via targeting cathepsin D signaling.

  2020cites this paper
• Effect of angiotensin receptor blockers on blood pressure and renal function in patients with concomitant hypertension and chronic kidney disease: a systematic review and meta-analysis

  2019cites this paper
• Treatment of nephrotic syndrome: going beyond immunosuppressive therapy

  2019cites this paper
• Diet quality and diet patterns in relation to circulating renal biomarkers in uninephrectomized rats

  2018cites this paper
• Renal blood flow and vascular resistance responses to angiotensin II in irreversible and reversible unilateral ureteral obstruction rats; the role of angiotensin II type 1 and 2 receptors

  2018cites this paper
• Cardiovascular System (C)

  2017cites this paper
• Pharmacological Induction of Kidney Regeneration

  2017cites this paper
• Effect of Statins on Patients and Graft Survival in Kidney Transplant Recipients: a Survival Meta-analysis.

  2017cites this paper
• Deoxycorticosterone Acetate/Salt–Induced Cardiac But Not Renal Injury Is Mediated By Endothelial Mineralocorticoid Receptors Independently From Blood Pressure

  2016cites this paper
• Disputes in the Treatment of Diabetic Nephropathy: The Dual Blockade of Renin-Angiotensin System.

  2016cites this paper
• Histone deacetylase inhibition, but not a mineralocorticoid receptor antagonist spironolactone, attenuates atypical transcription by an activating mutant MR (MRS810L)

  2016cites this paper
• Inhibiting angiotensin-converting enzyme promotes renal repair by modulating progenitor cell activation.

  2016cites this paper
• The next generation of therapeutics for chronic kidney disease

  2016cites this paper
• Tiotsetam Influence on Renal Function at Different Mineralocorticoid Activity in the Experiment

  2016cites this paper
• MicroRNA modulation of aldosterone production in the adrenal gland

  2016cites this paper
• Lysine deacetylase inhibition attenuates hypertension and is accompanied by acetylation of mineralocorticoid receptor instead of histone acetylation in spontaneously hypertensive rats

  2016cites this paper
• Endoplasmic reticulum stress drives proteinuria-induced kidney lesions via Lipocalin 2

  2016cites this paper
• A double-blind randomised study to evaluate the efficacy and safety of bindarit in preventing coronary stent restenosis.

  2016cites this paper
• Angiotensin II Type 1 Receptor (AT1R) Changes in Animal Model of Chronic Kidney Disease: Evaluation and Pharmacotherapy

  2016cites this paper
• Et and diabetic nephropathy: preclinical and clinical studies.

  2015cites this paper
• Transglutaminase 2 in Chronic Kidney Disease of the Domestic Feline and its role in a rodent model of Renal Warm Ischaemia

  2015cites this paper
• Recent Developments in Epigenetics of Acute and Chronic Kidney Diseases

  2015cites this paper
• Effects of combination of aliskiren and pentoxyfylline on renal function in the rat remnant kidney model of chronic renal failure

  2015cites this paper
• Lysine acetyltransferases cyclic adenosine monophosphate response element‐binding binding protein and acetyltransferase p300 attenuate transcriptional activity of the mineralocorticoid receptor through its acetylation

  2015cites this paper
• ZSF1 rat: a model of chronic cardiac and renal diseases in the context of metabolic syndrome. Characterization with anti-oxidant, mineralocorticoid receptor antagonist and aldosterone synthase inhibitor

  2015cites this paper
• ReviewThe role of renin angiotensin system inhibition in kidney repair

  2015cites this paper
• Integration of analytical techniques for protein biomarker assays.

  2014cites this paper
• Cellular mechanisms underlying the ACE inhibitor capacity to stimulate kidney self-repair

  2014cites this paper
• Retinoids and glomerular regeneration.

  2014cites this paper
• Mineralocorticoid receptor antagonist in heart failure: Past, present and future perspectives

  2014cites this paper
• Nitrosonifedipine Ameliorates the Progression of Type 2 Diabetic Nephropathy by Exerting Antioxidative Effects

  2014cites this paper
• Drugs to Foster Kidney Regeneration in Experimental Animals and Humans

  2014cites this paper
• Human Unrestricted Somatic Stem Cell Administration Fails to Protect Nude Mice from Cisplatin-Induced Acute Kidney Injury

  2013cites this paper
• Rosiglitazone Treatment of Type 2 Diabetic db/db Mice Attenuates Urinary Albumin and Angiotensin Converting Enzyme 2 Excretion

  2013cites this paper
• Targeting therapeutics to the glomerulus with nanoparticles.

  2013cites this paper
• Transforming growth factor-beta and the glomerular filtration barrier

  2013cites this paper
• Feline CKD

  2013cites this paper
• Bindarit, an anti-inflammatory agent, reduces neointimal hyperplasia in animal models of vascular injury

  2013cites this paper
• Chapter 87 – Role of Proteinuria in the Progression of Renal Disease

  2013cites this paper
• Renal progenitors in non-diabetic and diabetic nephropathies.

  2013cites this paper
• Proteinuria impairs podocyte regeneration by sequestering retinoic acid.

  2013cites this paper
• Pathophysiology and Complications of Diabetes Mellitus

  2012cites this paper
• Genetic Modification of Mesenchymal Stem Cells to Overexpress CXCR4 and CXCR7 Does Not Improve the Homing and Therapeutic Potentials of These Cells in Experimental Acute Kidney Injury

  2012cites this paper
• Renin–angiotensin–aldosterone system and the kidney

  2012cites this paper
• Impaired renal function in morbid obese patients with nonalcoholic fatty liver disease

  2012cites this paper
• Can we target tubular damage to prevent renal function decline in diabetes?

  2012cites this paper
• Mechanisms and treatment of CKD.

  2012cites this paper
• Current drug development challenges in chronic kidney disease (CKD)--identification of individualized determinants of renal progression and premature cardiovascular disease (CVD).

  2012cites this paper
• The Renin-Angiotensin-Aldosterone System in Renal and Cardiovascular Disease and the Effects of its Pharmacological Blockade

  2012cites this paper
• Spironolactone; the ultimate blocker of RAAS cascade in hypertensive patients with special reference to its cardiovascular benefits: Revisiting the forgotten ways

  2012cites this paper
• Bindarit Inhibits Human Coronary Artery Smooth Muscle Cell Proliferation, Migration and Phenotypic Switching

  2012cites this paper
• Targeting Tumors and the Kidney with siRNA Nanoparticles and Evaluation of Extracellular MicroRNA-based Methodologies to Track Their Activity

  2012cites this paper
• Etiopathology of chronic tubular, glomerular and renovascular nephropathies: Clinical implications

  2011cites this paper
• Endothelin in chronic proteinuric kidney disease.

  2011cites this paper
• Role of angiotensin II in the development of nephropathy and podocytopathy of diabetes.

  2011cites this paper
• Intermediate volume on computed tomography imaging defines a fibrotic compartment that predicts glomerular filtration rate decline in autosomal dominant polycystic kidney disease patients.

  2011cites this paper
• Role Of Hyperglycemia And Aldosterone On Renal ACE2 AND Albuminuria In db/db Mice

  2011cites this paper
• Fractional excretions of albumin and IgG are the best predictors of progression in primary glomerulonephritis.

  2011cites this paper
• Efeito do inibidor de TGF-β, GW-788388, sobre a infecção aguda experimental por Trypanosoma cruzi.

  2011cites this paper
• The Remission Clinic approach to halt the progression of kidney disease.

  2011cites this paper
• Effect of ACE inhibition on glomerular permselectivity and tubular albumin concentration in the renal ablation model.

  2011cites this paper
• New short interfering RNA-based therapies for glomerulonephritis

  2011cites this paper
• Relevance of light , fluorescence and transmission electron microscopy techniques to differential diagnoses of kidney allograft rejection

  2011cites this paper
• Inhibition of In-Stent Stenosis by Oral Administration of Bindarit in Porcine Coronary Arteries

  2011cites this paper
• Angiotensin II as a morphogenic cytokine stimulating renal fibrogenesis.

  2011cites this paper
• Chronic Allograft Nephropathy

  2011cites this paper
• The RAAS in the pathogenesis and treatment of diabetic nephropathy

  2010cites this paper
• Nondiabetic Kidney Disease

  2010cites this paper
• Renal Medicine 3 Kidney regeneration

  2010cites this paper
• PKC- Promotes Renal Tubular Cell Apoptosis Associated with Proteinuria

  2010cites this paper
• Kidney regeneration.

  2010cites this paper
• PKC-delta promotes renal tubular cell apoptosis associated with proteinuria.

  2010cites this paper
• Comparative proteomic analysis of rat aorta in a subtotal nephrectomy model

  2010cites this paper
• The role of renin angiotensin system inhibition in kidney repair

  2010cites this paper
• Obstructive renal injury: from fluid mechanics to molecular cell biology

  2010cites this paper
• Common pathophysiological mechanisms of chronic kidney disease: therapeutic perspectives.

  2010cites this paper
• Adding a statin to a combination of ACE inhibitor and ARB normalizes proteinuria in experimental diabetes, which translates into full renoprotection.

  2010cites this paper
• Effect of the Urotensin Receptor Antagonist Palosuran in Hypertensive Patients With Type 2 Diabetic Nephropathy

  2010cites this paper
• Non-immune interventions to protect kidney allografts in the long term.

  2010cites this paper
• Targeting the renin angiotensin system for remission/regression of chronic kidney disease.

  2010cites this paper
• Angiotensin II revisited: new roles in inflammation, immunology and aging

  2010cites this paper
• Recent Publications on Medications and Pharmacy

  2009cites this paper
• V1/V2 Vasopressin receptor antagonism potentiates the renoprotection of renin-angiotensin system inhibition in rats with renal mass reduction.

  2009cites this paper
• The anti-inflammatory agent bindarit inhibits neointima formation in both rats and hyperlipidaemic mice

  2009cites this paper
• Proteinuria: Is the ONTARGET renal substudy actually off target?

  2009cites this paper
• Amelioration of alphavirus-induced arthritis and myositis in a mouse model by treatment with bindarit, an inhibitor of monocyte chemotactic proteins.

  2009cites this paper
• Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes.

  2009cites this paper
• The global burden of chronic kidney diseases waits for better renoprotection

  2009cites this paper